about
A review on JC virus infection in kidney transplant recipients.ADPKD: clinical issues before and after renal transplantation.The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients.Carbon dioxide as a valuable contrast agent for identifying iatrogenic arteriovenous fistulas in transplanted kidneys.High frequency of Merkel cell polyomavirus DNA in the urine of kidney transplant recipients and healthy controls.Conversion from cyclosporine to tacrolimus for refractory acute rejection in pediatric kidney transplant recipients: a single-center experience.Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients.Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement.Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients.Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipient.One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.Longitudinal evaluation of mycophenolic acid pharmacokinetics in pediatric kidney transplant recipients. The role of post-transplant clinical and therapeutic variables.Pediatric kidney transplantation: a snapshot 10 years later.Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients.Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving A quadruple immunosuppressive regimen: the value of C2 blood levels.Nosocomial infection in kidney transplant recipients: a retrospective analysis of a single-center experience.Early experience with a newly developed electrospun polycarbonate-urethane vascular graft for hemodialysis access.Heterotopic cardiac xenotransplantation in rodents: report of a refined technique in a hamster-to-rat model.A two-year experience with a rapid access, self-sealing, polycarbonate urethane nanofiber vascular access graft for hemodialysis.Use of a newly developed ultrasound contrast medium for color Doppler evaluation in kidney transplantation.Successful medical treatment of EBV smooth muscle tumor in a renal transplant recipientInvestigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximabEffects of defibrotide on renal function and urinary prostanoid excretion in ciclosporin-treated ratsImmunosuppressive effects of defibrotideProtective effect of L-arginine on liver ischemia-reperfusion injuryNeoral versus Sandimmun in kidney-pancreas transplantationEffect of L-arginine and oligotide on liver ischemia-reperfusion injuryThe protective effects of L-arginine after liver ischaemia/reperfusion injury in a pig modelKidneys from border-age donors in the cyclosporine era: long-term function and outcomeTwenty-six year surgical experience of 259 pediatric transplants in 235 children and long-term follow-up of 181 under cyclosporine therapyLong-term function and survival rates of kidneys from extreme-age donors in the cyclosporine eraCyclosporine monitoring in stable, long-term, pediatric kidney transplant recipients: the value of C2 determinationInfluence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipientsCombined liver-kidney transplantation in glycogen storage disease Ia: a case beyond the guidelinesC2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipientsValue of intraoperative resistive index in kidney transplantC0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients: is there any threat for chronic rejection development?Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitorsComplement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery
P50
Q36602840-837BB8D8-6A36-4247-899D-BA4D65F6F19EQ38987102-833E79AA-02E5-44A9-A85C-A2A204174FADQ39591103-1C93F7A6-73C2-4102-940A-B01EE215F96CQ39661187-B312D2F5-5D39-4D96-A19D-A6F7C22450D8Q41622588-3371E7A3-E5C3-44D5-8706-142C51EFF154Q43828614-CC070FEC-2027-4424-A77B-89449F78AB3DQ44107562-74D188B7-5539-4300-B432-6E285CC1793AQ44285064-22729430-F173-45A5-8BC3-F3425C4A566AQ44522008-D9EB8A95-F952-4D9A-B47B-4E8C741A6FCEQ44839090-19A91B13-121B-4972-A5C1-189189E1E6D8Q44859922-CCD3F191-9133-4D69-A02D-E84D6D8B7D05Q45197114-28ABD96E-75D2-40A3-81BB-03E00D6955F0Q46134304-28B66271-EB46-400F-BA69-6A9EAC47564CQ46449563-5FDC5DFB-8303-425B-AECD-3D6E67FA500BQ46452789-F117F529-2214-4F8B-B6A2-6E77917F9F49Q46478188-4772164D-67F7-4359-AB79-7A96899F66E4Q47722327-5721229C-6412-40F1-B21B-0C64AEB0650DQ48021764-5DA27EBF-F369-4329-9D30-DC2ADF4338BCQ51234600-FEAB19AA-664E-465C-A6CC-E851769C7A78Q51404323-27218BE5-AF41-4A77-A873-BA4AFED7DAF3Q54102304-FDC32F52-C4C8-4FCA-B655-3F6ACBAD9BE1Q57275298-9A046F8C-B7B0-419B-8705-F3A245BB9EA3Q61716538-A22BB6AC-578C-481F-81E0-228CD57701E4Q67796095-EB199BB6-1D12-4F3C-AB6E-6D57EDC7DCDFQ72538110-3D0DC6C2-0A79-4E9B-8717-4E73D9395F7CQ73278100-4B8EE80D-4EE9-420A-9B47-99C53F988525Q73868891-B8C8F4C6-87C5-4520-89F5-322548D4C2DCQ73869072-B03FEAB1-6B55-46B0-98EC-DB53AB0E7083Q74295915-B7D28C18-62A3-4C33-899B-068508E07D3EQ74616056-196DB925-AE28-428D-A9AF-C3EF674D3122Q77176539-52B01F1F-9FBD-4419-89E9-BDAAB5DCCBDFQ77177065-39F72783-6DB0-413A-85EE-FA751D570434Q79997089-8AADE98A-5B2A-4151-8B30-A88AD597830FQ80149950-FB0F2188-3543-4D14-A20A-39ACA9C78109Q80213709-1F91AC3A-495A-4389-946E-D25AAF2FD413Q81202812-9ABDEF6C-AFE8-4F03-AD8E-50299D1598B9Q81258033-F3DCA801-1636-41FD-BED5-D893B90F0881Q81774910-6B865A3E-98E9-4C53-A2E8-F98C0848E473Q84787263-70AE840E-6C3C-4009-8A74-608DDF5720A0Q86868173-62A0A43A-D364-47C6-8D11-32888D1DB3AB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mariano Ferraresso
@ast
Mariano Ferraresso
@en
Mariano Ferraresso
@es
Mariano Ferraresso
@nl
Mariano Ferraresso
@sl
type
label
Mariano Ferraresso
@ast
Mariano Ferraresso
@en
Mariano Ferraresso
@es
Mariano Ferraresso
@nl
Mariano Ferraresso
@sl
prefLabel
Mariano Ferraresso
@ast
Mariano Ferraresso
@en
Mariano Ferraresso
@es
Mariano Ferraresso
@nl
Mariano Ferraresso
@sl
P1053
D-5485-2012
P106
P1153
35433758100
P1343
P21
P31
P3829
P496
0000-0003-3410-9090
P569
1961-01-01T00:00:00Z